Andolast, formerly known as CR-2039, an anti-allergic agent for the treatment of bronchial asthma, chronic obstructive pulmonary disease (COPD). Andolast acts at different cellular levels to inhibit immunoglobulin E synthesis. Andolast proved to be significantly more effective than placebo in improving airflow, and in controlling asthma symptoms both during day and night. References: Malerba M, D Amato M, Radaeli A, Giacovelli G, Rovati L, Arshad SH, Holgate ST. Efficacy of Andolast in Mild to Moderate Asthma: A Randomized, Controlled, Double-Blind Multicenter Study (The Andast Trial). Curr Pharm Des. 2015;21(26):3835-43. PubMed PMID: 25845448.

纯度：≥98%

CAS：132640-22-3